Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/28/2025 | Mkt Perform | William Blair | |
12/10/2024 | $40.00 → $5.00 | Overweight → Underweight | Morgan Stanley |
12/9/2024 | $42.00 → $7.00 | Buy → Hold | Jefferies |
12/9/2024 | $45.00 → $7.00 | Buy → Neutral | Citigroup |
10/21/2024 | $45.00 | Buy | Citigroup |
10/21/2024 | $42.00 | Buy | Jefferies |
10/21/2024 | $40.00 | Overweight | Morgan Stanley |
STOCKHOLM, Sweden, March 3, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ:BIOA) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia has declined the approval of lecanemab (generic name) as a treatment for early Alzheimer's disease (AD) (mild cognitive impairment due to AD and mild AD dementia). Eisai remains committed to ensuring eligible Australians with early Alzheimer's disease can access lecanemab and is exploring options to achieve this, including potentially seeking review by the Administrative Review Tribunal. In October 2024, the TGA made the decision not to register lecanemab in Australia for the treatment of patients
RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in one-on-one meetings at TD Cowen's 45th Annual Health Care Conference. TD Cowen's 45th Annual Health Care Conference is taking place on March 3–5, 2025, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and innovative panel discussions, moderated by members of the TD Cowen research team, that focus on various aspects of the health
Advancement of next-generation APJ agonists with discontinuation of azelaprag Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025 Expansion of discovery efforts based on insights from BioAge's platform, including a target identification collaboration with Novartis and a newly announced antibody therapeutics development collaboration with Lilly ExploR&D RICHMOND, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced compan
4/A - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
SCHEDULE 13G/A - BioAge Labs, Inc. (0001709941) (Subject)
SCHEDULE 13G - BioAge Labs, Inc. (0001709941) (Subject)
10-Q - BioAge Labs, Inc. (0001709941) (Filer)
William Blair initiated coverage of BioAge Labs with a rating of Mkt Perform
Morgan Stanley downgraded BioAge Labs from Overweight to Underweight and set a new price target of $5.00 from $40.00 previously
Jefferies downgraded BioAge Labs from Buy to Hold and set a new price target of $7.00 from $42.00 previously
SC 13G - BioAge Labs, Inc. (0001709941) (Subject)
SC 13G - BioAge Labs, Inc. (0001709941) (Subject)
SC 13D - BioAge Labs, Inc. (0001709941) (Subject)
4/A - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4/A - BioAge Labs, Inc. (0001709941) (Issuer)